exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088978 RNA Name: hsa-miR-5100 RNA Type: miRNA Chromosome: chr10 Starnd: + Coordinate: Start Site(bp): 42997630 End Site(bp): 42997651 External Links: hsa-miR-5100

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand SNU13 chr22 41673933 41690504 - GHITM chr10 84139509 84153568 + AGRN chr1 1020120 1056118 + PRRC2B chr9 131373636 131500197 + HNRNPH1 chr5 179614178 179634784 - GTF3C4 chr9 132670035 132694953 + PPCDC chr15 75023586 75117462 + SLC35B1 chr17 49700934 49709014 - SRP72 chr4 56467617 56503681 + SRPK1 chr6 35832966 35921342 - CHPF chr2 219538948 219543809 - NOP14 chr4 2937933 2963406 - SLC52A2 chr8 144354135 144361272 + THOP1 chr19 2785503 2815807 + MACF1 chr1 39081316 39487177 + CPTP chr1 1324756 1328896 + UBR4 chr1 19074510 19210266 - ZNF136 chr19 12163064 12189871 + HCN1 chr5 45254948 45696498 - NUP93 chr16 56730118 56850286 + KCTD2 chr17 75032575 75065889 + NIN chr14 50719763 50831121 - KDSR chr18 63327726 63367228 - ATP1A1 chr1 116372668 116410261 + PRMT6 chr1 107056674 107067636 + FLNA chrX 154348524 154374638 - NUP107 chr12 68686951 68745809 + P4HTM chr3 48989889 49007153 + VSIG10 chr12 118063593 118136026 - WASF2 chr1 27404230 27490167 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand POLR2J4 chr7 43940895 44019175 - SNHG3 chr1 28505980 28510892 + AC008738.2 chr19 33305036 33309387 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.